Stemline Therapeutics (STML) – Management Comments
-
Stemline Therapeutics (STML) Reports Prelim. FY19 Net Revenues for ELZONRIS (tagraxofusp); Highlights Commercial and Clinical Growth Drivers
-
Stemline Therapeutics (STML) Highlights ELZONRIS Phase 2 Clinical Data in CMML and MF at ASCO 2019 Meetings
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to STML Stock Lookup